Form 4: Cardiff Oncology COO Receives 400k Stock Option Grant

Cardiff Oncology Chief Operating Officer Ajay Aggarwal was granted 400,000 stock options with an exercise price of $1.72.

Summary

• Chief Operating Officer Ajay Aggarwal received a grant of 400,000 stock options on April 27, 2026.
• The options have an exercise price of $1.72 per share.
• The options expire on April 27, 2036.
• Vesting schedule: 100,000 options vest on April 27, 2027, followed by 8,333 options vesting monthly for 36 months starting May 27, 2027.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation, which is neutral for the stock price.

Positives

• Alignment of executive interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential for future shareholder dilution upon the exercise of these options.

Risks

• Market volatility affecting the value of the underlying common stock relative to the $1.72 exercise price.

Future Outlook

The grant indicates a long-term retention strategy for the Chief Operating Officer, with full vesting occurring over a four-year period.

Industry Context

StockSavvy.ai notes that equity grants for C-suite executives in the biotechnology sector are standard practice to incentivize long-term clinical and commercial development milestones.

Comparison to Industry Standards

• The four-year vesting schedule is consistent with standard corporate governance practices for executive equity compensation in the U.S. biotech industry.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of 100,000 options on April 27, 2027.
• Commencement of monthly vesting on May 27, 2027.

Key Dates

Keywords

Cardiff Oncology, CRDF, Form 4, Insider Trading, Stock Options, Executive Compensation